Lassen Therapeutics

Ownership

Private

Employees

~27

Therapeutic Areas

OncologyEndocrinologyPulmonology

Stage

Phase 1

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Monoclonal antibody

Lassen Therapeutics General Information

First patient dosed in Phase 1 trial for LASN01 in thyroid eye disease as of December 2023, with plans to advance to Phase 2 studies

Contact Information

Website

https://lassentherapeutics.com

Primary Industry

Biotech

Corporate Office

San Diego, California
United States

Drug Pipeline

LASN01

Phase 1

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Lassen Therapeutics's pipeline data

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Lassen Therapeutics Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Lassen Therapeutics's complete valuation and funding history, request access »

Lassen Therapeutics Financial Metrics